Background Antiplatelet therapy is recommended among patients with established
atherosclerosis. We compared monotherapy with a P2Y 12 inhibitor versus aspirin for …

Objective To assess the effects of different oral antithrombotic drugs that prevent saphenous
vein graft failure in patients undergoing coronary artery bypass graft surgery. Design …

Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Abstract Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study
Comparing Two Forms of Anti-platelet Therapy After Stent Implantation) study randomly …

Aim To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …

Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Objective To assess the effect of different antiplatelet strategies on clinical outcomes after
coronary artery bypass grafting. Design Five year follow-up of randomised Different …

Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …

Ticagrelor is a platelet P2Y12 receptor inhibitor approved for use in patients with acute
coronary syndromes, coronary artery disease, and low‐moderate risk acute ischemic stroke …